使用e-pharmacophore建模和基于大规模虚拟查的结构引导药物发现方法来识别固酶5A的选择性抑制剂
Arooma Maryam1,2,3,4, Abdul Rauf Siddiqi1, Sundeep Chaitanya Vedithi3
1Department of Biosciences, COMSATS University Islamabad (CUI), Islamabad, Pakistan.
Journal of biomolecular structure & dynamics
|August 7, 2023
概括
研究人员确定了新型选择性酶5A (PDE5A) 抑制剂,对于心血管疾病至关重要. 这些化合物对PDE5A比PDE6A具有很高的特异性,为新的治疗干预提供了潜力.
科学领域:
- 心血管药理学心血管药理学
- 药用化学 医学化学
- 计算生物学 计算生物学
背景情况:
- 固酶5A (PDE5A) 抑制是心血管疾病的治疗点,包括肺动脉高血压.
- 开发选择性PDE5A抑制剂至关重要,以最大限度地减少非目标效应,特别是与PDE6A的交叉反应.
研究的目的:
- 使用计算方法发现新型,高度选择性的PDE5A抑制剂.
- 为了区分PDE5A和PDE6A催化域之间的抑制剂结合亲和力和特异性.
主要方法:
- 使用大型化合物数据库 (CoCoCo) 的电子药物选.
- 使用Glide对接,分子动力学 (MD) 模拟和MM-GBSA进行绑定分析.
- 评估化合物是否符合利宾斯基的五项规则和ADME/毒素标准.
主要成果:
- 确定了1536427,4832637和6788240作为PDE5A的稳定,紧密的结合剂,显示出对PDE6A的选择性.
- MD模拟证实了化合物1536427与PDE5A催化核心的稳定结合,与PDE6A相比有明显的构造变化.
- 化合物1536427在PDE6A中表现出明显不同的相互作用和动态,表明特异性较低.
结论:
- 这项研究成功地确定了具有有利药物样性质的潜在选择性PDE5A抑制剂.
- 化合物1536427对PDE5A比PDE6A具有有前途的选择性,需要进一步调查.
- 这些发现可能会导致心血管疾病的改善治疗方法的开发.
更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.2K
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.3K
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
189
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
189
Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
Protein Kinases and Phosphatases
13.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.2K
Structure-Activity Relationships and Drug Design
769
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
769
